Pharm-Olam International Ltd., a Houston, Texas-based full-service clinical research organization (CRO), serving the biopharmaceutical and medical device industries, recently received a private equity investment from Quad-C Management.
The terms of the transaction were not disclosed. Concurrent with the transaction, David Grange, who has been working with Quad-C for over a year, will be joining the Pharm-Olam board as Vice Chairman.
The company intends to use the proceeds from the investment to accelerate growth, while actively pursuing strategic acquisitions to add new services and/or geographical capabilities.
Founded in 1994 by Dr. Zev Munk and Eugene Barg, who are retaining a significant ownership stake in the company, Pharm-Olam International is a multinational Contract Research Organization (CRO) offering comprehensive clinical research services to the pharmaceutical, biotechnology and medical device industries. From Phase I to Phase IV, the organization focuses on delivering quality data, achieving targeted enrollment and meeting projected timelines, making clinical research as Easy As I, II, III, IV™.
Pharm-Olam has 27 offices worldwide and has supported clinical trials in over 60 countries. The company’s European headquarters are based in Ascot, England.